fda semaglutide shortage resolved feb 21 2025 clarifies policies for compounders as national GLP-1 supply begins to stabilize The FDA Removes Semaglutide from

5 Investigates looked up the credentials of the doctors and found that one was a dermatologist, while the other was an OBGYN

Recurrent infections (four or more annually) require medical evaluation, vaginal swabs for culture, and assessment of underlying metabolic control

Clinical considerations : -Noncirrhotic MASH: There may be risks to the mother and fetus related to MASH with advanced liver fibrosis (e.g., increased risks of gestational diabetes, hypertensive complications, preterm birth, postpartum hemorrhage)

Increased heart rate: A resting heart rate that suddenly feels fast or pounding should be reported to your provider

If you are weighing options, semaglutide produces less diarrhea but also less weight loss